AI Cure is a research tool showing open data. Not medical advice. Discuss with your doctor. Terms

โ† Trials
๐Ÿงช

Establishment of a Multi-omics Prediction Model for Early Triple-negative Breast Cancer Based on UPGRADE-TNBC Study

Recruitingn/aAges 18 Years - 75 YearsFemaleCancer Institute and Hospital, Chinese Academy ofโ€ฆ
๐Ÿ’ฌ

In plain words

What the trial is, and whether it could suit you

Based on the UPGRADE-TNBC study, a high-quality TNBC sample repository was established. By integrating multi-source data-including clinical information, radiomics, pathological images, and molecular sequencing-and innovatively incorporating a meta-learning strategy, a treatment response prediction model based on multimodal small-sample learning was developed. This approach aims to optimize drug combinations and precisely identify patient subgroups likely to benefit from treatment, thereby providing a new paradigm for personalized therapy in early-stage TNBC.

Sign in to get the eligibility rules as simple questions to take to your doctor.

๐Ÿ“‹ Eligibility rules (as published)
Inclusion Criteria: * The UPGRADE-TNBC Study Population Exclusion Criteria: * Populations outside the UPGRADE-TNBC study
๐Ÿ’Š

What it tests

  • Collect data
๐Ÿ“

Where

1 site
Cancer Hospital, Chinese Academy of Medical Sciences
Beijing, China
๐Ÿค Taking part is your choice, and you can leave at any time. Only the trial team can confirm you are eligible โ€” always decide together with your own doctor.
๐Ÿ›ก๏ธ

AI Cure shows public evidence (Open Targets, ClinicalTrials.gov, PubMed, openFDA, DepMap, AlphaFold) with its source, and AI summaries that cite it โ€” not medical advice and not a cure. Treatment decisions belong with your doctor. Research ideas are shared only with approved researchers and labs, who can test them. In an emergency call your local emergency number (112 in India and Europe, 911 in the US). AI Cure Terms of Use ยท Privacy